Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness

Detalhes bibliográficos
Autor(a) principal: Guerreiro Castro, S
Data de Publicação: 2017
Outros Autores: Isenberg, D
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/2680
Resumo: Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.
id RCAP_74879813f06c92b60d723bbb4ac28971
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/2680
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical UsefulnessHCC MEDBelimumabBiologic TherapyImmunosuppressive AgentsSystemic Lupus ErythematosusSystemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.SAGE PublicationsRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEGuerreiro Castro, SIsenberg, D2017-04-19T15:12:26Z2017-032017-03-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/2680engTher Adv Musculoskelet Dis. 2017 Mar;9(3):75-8510.1177/1759720X17690474info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:39:06Zoai:repositorio.chlc.min-saude.pt:10400.17/2680Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:20:01.098342Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
title Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
spellingShingle Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
Guerreiro Castro, S
HCC MED
Belimumab
Biologic Therapy
Immunosuppressive Agents
Systemic Lupus Erythematosus
title_short Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
title_full Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
title_fullStr Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
title_full_unstemmed Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
title_sort Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
author Guerreiro Castro, S
author_facet Guerreiro Castro, S
Isenberg, D
author_role author
author2 Isenberg, D
author2_role author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Guerreiro Castro, S
Isenberg, D
dc.subject.por.fl_str_mv HCC MED
Belimumab
Biologic Therapy
Immunosuppressive Agents
Systemic Lupus Erythematosus
topic HCC MED
Belimumab
Biologic Therapy
Immunosuppressive Agents
Systemic Lupus Erythematosus
description Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.
publishDate 2017
dc.date.none.fl_str_mv 2017-04-19T15:12:26Z
2017-03
2017-03-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/2680
url http://hdl.handle.net/10400.17/2680
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85
10.1177/1759720X17690474
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131296931250176

Registros relacionados